Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 10/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8615064 | 0.78 | ALDH1A1 (0.37) | ALDH1A1MAPTHRH3SLC6A4 | |
| SCHEMBL8128972 | 0.76 | ALDH1A1 (0.42) | ALDH1A1MAPTAR | |
| SCHEMBL8588306 | 0.73 | IKBKB (0.40) | ALDH1A1MAPTHRH3 | |
| SCHEMBL8616789 | 0.73 | SLC6A4 (0.43) | ALDH1A1MAPTSLC6A4HTR7 | |
| SCHEMBL8613634 | 0.71 | UTS2R (0.39) | ALDH1A1MAPT | |
| SCHEMBL8116119 | 0.70 | MAPT (0.44) | ALDH1A1MAPTAR | |
| SCHEMBL8613696 | 0.69 | HRH3 (0.44) | ALDH1A1MAPTHRH3 | |
| SCHEMBL8617695 | 0.69 | NOTUM (0.43) | ALDH1A1MAPT | |
| SCHEMBL23063842 | 0.66 | ALDH1A1 (0.53) | ALDH1A1MAPTAR | |
| SCHEMBL8617442 | 0.65 | CHRNB4 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998050346-A2 | ACETAMIDE AND UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |